Lemtrada (LEM-trah-dah, alemtuzumab) will be a new IV option for relapsing-remitting forms of multiple sclerosis (MS)

June 2014

Lemtrada (LEM-trah-dah, alemtuzumab) will be a new IV option for relapsing-remitting forms of multiple sclerosis (MS) in Canada.

It's for patients who don't respond adequately to interferon beta (Rebif, etc) or other disease-modifying therapies.

Lemtrada may be more effective than interferon beta.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscription Options

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

Diabetes questions about when and how to use insulin
E-Cigarettes nicotine toxicity associated with e-cigarettes
Contraceptives Lolo (LOH-loh), the new lowest-dose combined oral contraceptive
Contraceptives Women often ask how to handle missed doses of an oral contraceptive
Infectious Diseases Summer will bring questions about treating swimmer's ear
Dermatology Onreltea (on-REL-tee-ah) is a new brimonidine gel for ROSACEA
Women's Health if antidepressants are safe during pregnancy
Multiple Sclerosis Lemtrada (LEM-trah-dah, alemtuzumab) will be a new IV option for relapsing-remitting forms of multiple sclerosis (MS)
Neurology & Pain ensure opioids are being used in the right patients
Cardiology how to safely use ACEIs or ARBs in patients with chronic kidney disease
Respiratory & Allergy Ragwitek will be the third new sublingual immunotherapy
Delirium more focus on preventing and treating delirium
Antithrombotics more interest in ORAL options to prevent blood clots after hip or knee replacement surgery